Residency · Residency · Medical Genetics Genomics
Autosomal Dominant Inheritance: Penetrance, Expressivity, and Anticipation
Core Principles of Autosomal Dominant Inheritance
Definition and Characteristics
In autosomal dominant inheritance, a single pathogenic variant on one allele of an autosomal gene is sufficient to cause disease. Affected individuals are typically heterozygous, carrying one normal allele and one mutant allele. The hallmark pedigree pattern is vertical transmission, with affected individuals appearing in every generation when the condition is fully penetrant. Males and females are equally affected, and male-to-male transmission is possible, which is the key feature distinguishing autosomal dominant from X-linked inheritance. Each offspring of an affected individual has a 50% chance of inheriting the pathogenic variant. Homozygosity for dominant conditions is rare and often produces a more severe phenotype than heterozygosity; for example, homozygous achondroplasia is lethal.
Mechanisms of Dominance
Several molecular mechanisms explain why a single mutant allele causes disease. In haploinsufficiency, one functional copy of the gene is insufficient to produce enough protein for normal function, as seen with PAX6 in aniridia and TCOF1 in Treacher Collins syndrome. Gain-of-function mutations cause the mutant protein to acquire a new or enhanced activity, exemplified by the activating FGFR3 mutations in achondroplasia and PIK3CA mutations in overgrowth syndromes. In dominant-negative effects, the mutant protein interferes with the function of the normal protein, as occurs with COL1A1 structural variants in severe osteogenesis imperfecta and TP53 missense mutations. Finally, the loss of heterozygosity model applies to tumor suppressor genes such as RB1 in retinoblastoma, where an inherited heterozygous germline variant is followed by somatic loss of the remaining wild-type allele.
Variable Expressivity
Definition
Variable expressivity refers to the phenomenon in which different individuals carrying the same pathogenic variant manifest different features or different severities of the associated disease. It describes the spectrum of clinical manifestations that can arise from a single gene or variant.
Clinical Examples
Neurofibromatosis type 1 provides a striking example: the same NF1 variant within a family may produce only cafe-au-lait macules in one individual, plexiform neurofibromas and optic glioma in another, and learning disabilities with minimal cutaneous findings in a third. In Marfan syndrome, FBN1 variants cause variable involvement of the skeletal, ocular, and cardiovascular systems even within the same family. Tuberous sclerosis, caused by TSC1 or TSC2 variants, can range from skin findings only to severe epilepsy and intellectual disability. Waardenburg syndrome, caused by PAX3 or MITF variants, shows variable presence of sensorineural hearing loss, heterochromia, and white forelock.
Contributing Factors
Several factors contribute to variable expressivity, including modifier genes (the broader genetic background), stochastic developmental variation, epigenetic factors, environmental influences, and somatic mosaicism, particularly when the variant arose post-zygotically and affects tissues differentially.
Reduced Penetrance
Definition
Penetrance is the proportion of individuals carrying a pathogenic variant who manifest any clinical features of the associated condition. When penetrance is less than 100%, some carriers are clinically unaffected. Importantly, a genotype-positive but phenotype-negative individual can still transmit the variant to offspring who may then be affected.
Clinical Examples
BRCA1 and BRCA2 demonstrate significant reduced penetrance: breast cancer penetrance is 45 to 72% for BRCA1 and 27 to 56% for BRCA2 by age 70, meaning not all carriers develop cancer. LMNA mutations causing dilated cardiomyopathy show age-dependent penetrance, with most carriers asymptomatic until adulthood. HFE C282Y homozygosity produces clinical hemochromatosis in only about 28% of male homozygotes and roughly 1% of female homozygotes. Retinoblastoma (RB1) has approximately 90% penetrance, but some obligate carriers remain unaffected. PRRT2 variants causing benign familial infantile epilepsy show reduced penetrance, with some carriers manifesting only paroxysmal kinesigenic dyskinesia.
Age-Dependent Penetrance
Many dominant conditions show increasing penetrance with age, a phenomenon that is essential for genetic counseling. A young individual who is currently asymptomatic may develop disease later in life. Penetrance tables stratified by age are available for some conditions, including Huntington disease, BRCA1/2-associated cancers, and hypertrophic cardiomyopathy. Kaplan-Meier penetrance curves provide actuarial estimates of disease-free survival among carriers.
Clinical Implications of Reduced Penetrance
When penetrance is reduced, the family history may appear to "skip" generations, creating a pseudoautosomal recessive pattern. Non-penetrant obligate carriers complicate genetic counseling. Variant classification must account for known reduced penetrance to avoid false reassurance. Surveillance recommendations should apply to all genotype-positive individuals regardless of their current phenotype.
De Novo Mutations
Frequency and Significance
A substantial proportion of dominant conditions arise from de novo mutations not present in either parent. The de novo rate varies by gene: approximately 80% of achondroplasia cases, about 50% of NF1 cases, and roughly 25% of Marfan syndrome cases arise de novo. The human de novo point mutation rate is approximately 1 to 1.5 times 10 to the negative 8th per nucleotide per generation, translating to about 50 to 100 new variants per genome per generation. There is a well-documented paternal age effect: most de novo point mutations arise from the paternal germline due to continuous spermatogonial cell division, with risk increasing approximately 2% per year of paternal age.
Germline Mosaicism
A parent who is apparently unaffected and tests negative on blood DNA may carry the pathogenic variant in a subset of their germ cells. Germline mosaicism is estimated to account for 5 to 10% of "de novo" cases depending on the gene. The recurrence risk for a truly de novo event in a non-mosaic parent is approximately 1%, accounting for the possibility of undetected germline mosaicism. Some genes have higher empiric rates of germline mosaicism, including FGFR3 at about 3%, COL1A1/COL1A2 at up to 7%, and DMD at 14 to 20% for Duchenne muscular dystrophy. Deep sequencing at high coverage (such as 500x) of parental blood or other tissues can detect low-level mosaicism.
Anticipation
Definition
Anticipation is a pattern in which disease severity increases or age of onset decreases in successive generations. It is characteristic of trinucleotide repeat expansion disorders and other tandem repeat expansion conditions.
Molecular Basis
Unstable expanded repeat alleles tend to further expand during meiotic transmission. Larger expansions generally correlate with earlier onset and more severe disease. The threshold between normal and pathogenic repeat lengths is gene-specific. Intermediate or premutation alleles may be unstable and can expand into the pathogenic range in subsequent generations.
Key Repeat Expansion Disorders
| Disorder | Gene | Repeat | Normal | Pathogenic | Parent of Origin Bias |
|---|---|---|---|---|---|
| Huntington disease | HTT | CAG | 6-26 | >=40 | Paternal expansion |
| Myotonic dystrophy 1 | DMPK | CTG | 5-34 | >=50 | Maternal for congenital form |
| Spinocerebellar ataxias (SCA1,2,3,6,7) | Various | CAG | Variable | Variable | Often paternal |
| Fragile X syndrome | FMR1 | CGG | 5-44 | >200 (full) | Maternal (premutation to full) |
| Friedreich ataxia | FXN | GAA | 5-33 | >66 | Autosomal recessive, not AD |
Myotonic Dystrophy Type 1 as a Paradigm
Myotonic dystrophy type 1 exemplifies anticipation and repeat-length correlation with severity. The mild form (50 to 150 repeats) manifests as cataracts and mild myotonia in adulthood. The classic form (100 to 1,000 repeats) features progressive myotonia, weakness, cardiac conduction defects, and cataracts. The congenital form (greater than 1,000 repeats) causes severe neonatal hypotonia, respiratory failure, and intellectual disability; it is nearly always maternally transmitted. The disease mechanism involves RNA toxic gain of function: expanded CUG repeats in the mRNA sequester the MBNL1 splicing factor, causing widespread splicing dysregulation across many genes.
Genetic Counseling Considerations
Risk Assessment
Bayesian analysis may be required when penetrance is incomplete or when integrating clinical, imaging, and genetic data. The prior probability of 50% for offspring of an affected individual is modified by posterior evidence, such as a normal age-appropriate evaluation that reduces the residual risk. Joint probability calculations incorporate age-dependent penetrance tables to refine estimates.
Reproductive Options
When the familial variant is known, prenatal diagnosis through CVS or amniocentesis is available. Preimplantation genetic testing for monogenic disorders (PGT-M) offers another option. Special considerations arise in situations such as nondisclosure PGT for Huntington disease, where a parent does not wish to know their own genetic status. Gamete donation is an alternative for those who wish to eliminate any transmission risk entirely.
<image>A multi-generational pedigree demonstrating autosomal dominant inheritance with variable expressivity and reduced penetrance. The proband in generation III has a severe phenotype (filled symbol). In generation II, one parent is mildly affected (partially filled symbol) and the other is unaffected. In generation I, the affected grandparent is shown with intermediate severity. One individual in generation II carries the pathogenic variant but is clinically unaffected (shown as an unfilled symbol with a dot indicating carrier of the variant), demonstrating reduced penetrance. Text annotations indicate specific clinical features present in each affected individual to illustrate variable expressivity.</image>
<image>A molecular diagram illustrating the mechanisms of dominance. Four panels: (1) Haploinsufficiency showing a cell with 50% protein output from one normal allele and one null allele, with a threshold line showing this is below the level needed for normal function. (2) Gain-of-function showing a constitutively active receptor (e.g., FGFR3) with continuous downstream signaling even without ligand. (3) Dominant-negative effect showing mutant collagen chains incorporating into trimers with normal chains and disrupting the entire helix structure. (4) Two-hit model showing a cell with one inherited mutant allele losing the second wild-type allele through LOH, leading to tumor formation.</image>
<image>A diagram of trinucleotide repeat expansion and anticipation across three generations. A DNA strand is shown with a CAG repeat tract. In Generation I, a normal-length repeat (22 repeats) is depicted. In Generation II, a mildly expanded allele (38 repeats, "premutation" range) is shown with late-onset mild symptoms. In Generation III, a fully expanded allele (55 repeats) is shown with early-onset severe disease. Arrows between generations show meiotic instability with progressive expansion. A severity/age-of-onset graph on the right shows the inverse correlation between repeat length and age of onset.</image>
Clinical Pearls
Male-to-male transmission excludes X-linked inheritance and is the key pedigree feature confirming autosomal dominant inheritance. Approximately 50 to 80% of cases of many autosomal dominant conditions are de novo, making a negative family history insufficient to exclude a dominant genetic etiology. Germline mosaicism creates a recurrence risk of approximately 1 to 7% (gene-dependent) for apparently de novo dominant conditions, and parents should be counseled accordingly. Variable expressivity means that a mildly affected parent may have a severely affected child; the severity in the parent does not predict severity in offspring. Age-dependent penetrance is critical for counseling, as a negative evaluation at age 20 does not definitively exclude future disease for many cardiac, neurological, and cancer predisposition genes. Repeat-primed PCR or Southern blot is required to detect trinucleotide repeat expansions, since standard NGS short-read sequencing does not reliably detect or size expanded repeats. When anticipation is suspected, it should always be confirmed with molecular testing rather than relying on clinical impression alone, as ascertainment bias can mimic apparent anticipation.
References
- Biesecker LG, Harrison SM. The ACMG/AMP reputable source criteria for the interpretation of sequence variants. Genet Med. 2018;20(12):1687-1688.
- Campbell IM et al. Parental somatic mosaicism is underrecognized and influences recurrence risk of genomic disorders. Am J Hum Genet. 2014;95(2):173-182.
- Rahbari R et al. Timing, rates and spectra of human germline mutation. Nat Genet. 2016;48(2):126-133.
- Paulson H. Repeat expansion diseases. Handb Clin Neurol. 2018;147:105-123.
- Firth HV, Hurst JA. Clinical Genetics and Genomics. Oxford University Press. 2017.
